Skip to Content

Exelixis Inc EXEL

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Contact
1851 Harbor Bay Parkway
Alameda, CA, 94502
T +1 650 837-7000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Slow Growth
Employees 773

Related